Akt

Akt (protein kinase B, PKB) is a serine/threonine kinase family that functions as a central effector of phosphatidylinositol 3-kinase (PI3K) signaling and regulates cell survival, proliferation, metabolism, apoptosis suppression, and glucose homeostasis through phosphorylation-dependent signaling networks^[1][2]. Akt activation occurs after PI3K-generated phosphoinositides recruit Akt to the plasma membrane, where phosphorylation at conserved regulatory residues enables full kinase activity and downstream signaling toward substrates involved in growth and metabolic control^[2][3]. Mechanistically, Akt signaling integrates growth factor, insulin, cytokine, and receptor-mediated inputs, thereby linking extracellular stimulation to cellular biosynthesis, survival, and metabolic adaptation^[2][4]. Dysregulated Akt signaling is strongly associated with cancer, diabetes, cardiovascular disorders, and immune-mediated diseases, making the pathway a major experimental and therapeutic target^[2][4][5]. The Akt family comprises three highly homologous isoforms, Akt1, Akt2, and Akt3, encoded by distinct genes but exhibiting partially nonredundant biological functions^[1][4]. Compared with related isoforms, Akt1 is primarily associated with cell growth, proliferation, and tumor initiation, whereas Akt2 contributes more strongly to glucose metabolism, cell migration, invasion, and metastatic progression^[1][5]. Akt3 shows enriched expression in neural tissues and has been implicated in brain development and selected malignancies, including melanoma models^[1][5]. For experimental applications, both pan-Akt and emerging isoform-selective inhibitors are widely used to investigate pathway dependence, therapeutic resistance, and isoform-specific signaling mechanisms in disease models^[5][6].